Research can be all consuming, sometimes you have to stop and look around.....
Fuelling the qest for the next generation of clinician scientists. Great opportunity!
Proximity induced degradation has only just begun!
Seville (bitter) oranges some times used for marmalade or juice but not usually edible as an oranges contain furanocumarins, CYP3A4 inhibitors that increase levels of drugs metabolised by CYP3A4.
At ##AACR26 , great to see the Cancer Therapeutics podium filled by ex Drug Development Unit fellows who are now Profs all across the world! @icr.ac.uk @royalmarsden.org . 👏👏👏
Its a honour to be appointed as a NIHR Senior Investigator. The NIHR has kept research at the forefront of the NHS and allows us to perform patient centric, scientifically robust research. @icr.ac.uk @royalmarsden.org @nihr.bsky.social
At #AACR26. Leveraging cancer stroma to deliver anticancer drugs. Fibroblast co-culture experiments in PDAC and sarcoma cell lines to study the role of AVA6000 a FAP activated doxorubicin prodrug as a single agent and in combination. @icr.ac.uk @crukconvergence.bsky.social
PhD convocation ceremony at @icr.ac.uk with DrDr Alvaro Graces. His thesis entitled Clonal Dynamics and evolutionary pathways in high grade serous ovarian cancer under therapeutic pressure siggests our current use of chemotherapy can be better optimised. @trevorgraham.bsky.social
The intersection of the PI3K/AKT pathway and immunotherapy. ICECAP study led by Prof Juanita Lopez. pubmed.ncbi.nlm.nih.gov/42043781/ @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
At #AACR26 Poster 6457.CD137 agonist. Exciting responses in breast cancer and high spec pharmacodynamic imaging showing decreasing metabolism (FDG-PET) but increasing lymphocytic infiltration (CD8 PET). @icr.ac.uk @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
Udai Banerji
The @US_FDA approved the protein degrader vepdegestrant for adults with previously treated ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations: buff.ly/B0gPzIW
American Association for Cancer Research (AACR)
❗One week left to apply for our intercalated #PhD (iPhD) ⌛
If you're a medical student interested in becoming a clinician-scientist, check out our PhD projects for 2026. 👇
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
🩺 Are you a #MedStudent doing an iBSc? We're looking for future clinician-scientists to join our intercalated #PhD ( #iPhD) programme in 2026.
Explore projects & apply by 20 Nov 👉 bit.ly/48YA5Tp
Please share with your networks!
#CancerResearch #ConvergenceScience #CRUKFunded
